MedTrace Logo

A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone

NCT00545129 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2021-06-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the safety and efficacy of tanezumab in combination with opioids in treating pain due to cancer that has spread to bone.

Conditions

  • Neoplasm Metastasis
  • Palliative Care

Interventions

DRUG

Tanezumab 10 mg IV

Single IV infusion of 10 mg tanezumab on Day 1. Maintained on baseline opioid regimen.

DRUG

IV Placebo for tanezumab

Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-29
Primary Completion
2011-12-24
Completion
2012-02-07

Countries

  • United States
  • Austria
  • Bosnia and Herzegovina
  • Croatia
  • France
  • Hungary
  • India
  • Latvia
  • Mexico
  • Peru
  • Poland
  • Slovakia
  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00545129 on ClinicalTrials.gov